SHARx Says Pharmacy Benefits Have Become a Major Spend Category With No Clear Owner
SHARx says pharmacy benefits have become one of the employer's largest healthcare spend, yet responsibility remains frag …
From Wrong Answers to Wrong Actions: The New Risk of Agentic AI in Life Sciences
As AI agents move deeper into regulated scientific workflows, AINGENS argues that autonomy must be bound by evidence, tr …
Wisner Baum's Lawsuits Challenge FDA Oversight of Spinal Cord Implants
Wisner Baum has filed state and federal lawsuits alleging spinal cord stimulators marketed as safe and effective for chr …
Four in Five Private Jet Buyers May Be Better Served with Other Products, FlyUSA Says
FlyUSA breaks down when charter, membership, jet cards, fractional access or ownership make sense, helping travelers avo …
Good Employers Keep Choosing the Wrong PBM Because They Start With the Wrong Metrics
Employers still rely too heavily on discounts and rebates to shortlist Pharmacy Benefit Managers (PBMs), according to US …
Good Employers Keep Choosing the Wrong PBM Because They Start With the Wrong Metrics
Employers still rely too heavily on discounts and rebates to shortlist Pharmacy Benefit Managers (PBMs), according to US …
Trace3 Says AI's Production Gap Is Not a Technology Problem
As AI moves from pilots into production, Trace3 says the real test is no longer whether the technology works, but whethe …
Insurance Coverage Doesn't Guarantee Medication Access, SHARx Says
Prior authorizations, formulary exclusions, step therapy, and specialty pharmacy restrictions can delay treatment even w …
AI in the Courtroom Is Becoming a Malpractice Risk for Law Firms, Wisner Baum Warns
With AI hallucinations increasingly showing up in legal filings, law firms face a new professional responsibility challe …
The $10B TAVR Market Grew. Why Are Most Patients Still Untreated?
After decades of device-delivery progress, the next era of TAVR must be judged by valve design, physiologic blood flow, …
